Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.54 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651490 | 0.86 | FLT3 (0.45) | FLT3BRD4KDM4EMEN1KMT2A | |
| SCHEMBL5648785 | 0.86 | HPSE (0.53) | FLT3BRD4KDM4EMEN1KMT2A | |
| SCHEMBL5649082 | 0.84 | CYP2D6 (0.53) | PDE5AKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5652589 | 0.84 | FLT3 (0.49) | FLT3BRD4MEN1KMT2A | |
| SCHEMBL5649792 | 0.82 | PRSS12 (0.49) | FLT3BRD4 | |
| SCHEMBL5651088 | 0.81 | PDE2A (0.52) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5651531 | 0.80 | FLT3 (0.58) | FLT3BRD4KDM4EMEN1ALDH1A1 | |
| SCHEMBL5651510 | 0.80 | FLT3 (0.65) | FLT3BRD4 | |
| SCHEMBL5652227 | 0.80 | FLT3 (0.49) | FLT3BRD4 | |
| SCHEMBL5652238 | 0.80 | FLT3 (0.47) | FLT3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | PDE5A 3793/4885FLT3 1968/4885PDE4A 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.